Balancing Safety and Efficacy in the Treatment Hodgkin Lymphoma: Early Discontinuation of Certain Drugs Can and Should Be Done
Journal of Clinical Oncology (JCO) Podcast · Alison Moskowitz
June 22, 20158m 35s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Analogous to prior analyses with ABVD, in a large series of Hodgkin lymphoma patients treated with BEACOPP, Haverkamp and colleagues from the German Hodgkin Study Group report that early discontinuation of bleomycin or vincristine due to toxicity has no impact on cure rates or survival.